- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01236833
Lactated Ringer's Solution in Neonates With Feeding Intolerance (LR)
Enteral Administration of Lactated Ringer's Solution in Neonates With Feeding Intolerance, a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Feeding intolerance is a common problem in premature infants in the Neonatal Intensive Care Unit. Definition is clinical and based on abdominal distension, abdominal tenderness, emesis, change in gastric residuals, presence of blood in stool, and apnea with bradycardia.
Feeding intolerance is associated with serious complications: necrotizing enterocolitis, longer hospitalization and prolonged intravenous nutrition complications (e.g. sepsis, liver damage). Therefore, the investigators aim to achieve adequate enteral nutrition as soon as possible.
Because LR is a an amniotic fluid-like solution, it may improve gastro-intestinal function and avoid fasting, as well as its multiple problems (e.g. intestinal atrophy and decreased intestinal motility). LR was chosen as the test solution because of experience documenting its safe use in comparable groups: in newborn resuscitation parenterally, in amnioinfusion, and in bowel irrigation. Moreover, LR is similar in electrolytes composition to the experimental solution used in previous studies by Barney et al in neonates.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Jewish General Hospital
-
Montreal, Quebec, Canada, H3H 2R9
- McGill University Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Birth gestational age (GA) between 25 and 32 weeks
- Corrected gestational age less than 34 weeks
- Enteral feeding tolerated at a minimum of 10 ml/kg/day for a minimum of 48 hours
Severe feeding intolerance, defined as a minimum of one or more of the following signs leading to withholding of milk feedings on two evaluations over 12 to 24 hours:
- Significant increased abdominal girth, as evaluated by the treatment team, with abdominal tenderness
- Visible enlarged bowel loops with abdominal tenderness
- Recurrent emesis leading to withhold feeds
- Gastric residuals in excess of one feeding, recurrent or with growing abdominal girth
- Visible blood in stools without anal etiology
- Documented informed consent for participation in the study
Exclusion Criteria:
- Infants who already reached full enteral feeds for 72 hours, in fact a minimum of 130 ml/kg/day enteral feeds without parenteral supplementation.
- Small for gestational age (SGA) (weight at or less than the 3rd percentile on the Fenton growth chart)
- NEC (Bell's stage II or higher, radiologic evidence of NEC, pneumatosis intestinalis or free intraperitoneal air)or history of NEC
- Gastric or intestinal occlusion (no transit, absent bowel sounds, incessant vomiting, bile stained vomiting or air fluid levels)
- Major congenital malformation
- Septic infants requiring therapeutic antibiotics or antimycotics (infants only on prophylactic antibiotics or antimycotics should not be excluded).
- Patients judged as being too ill to enroll in this study, as defined by a requirement for mechanical ventilation with >50% FIO2
- Patent Ductus Arteriosus requiring ibuprofen, indomethacin or ligature, until one week after the end of treatment
- Intraventricular Haemorrhage grade 3 or 4
- Hypernatremia ≥ 150 mmol/L
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Fasting
|
|
Active Comparator: Lactated Ringer's Solution
|
2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average of the daily enteral caloric intake (in calories/kg/day) received over the 14 days after study entry
Time Frame: 14 days
|
To measure enteral caloric intake, the volume of milk feeding, for each patient will be recorded daily and for 14 days.
Unfortified milk and fortified milk are calculated as containing respectively 0.67 Cal/ml and 0.81 Cal/ml.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of days to reach 130 ml/kg milk feeding
Time Frame: variable
|
variable
|
Number of days to discontinue IV access
Time Frame: variable
|
variable
|
Growth (weight, height, head circumference), increase % after 14 days and between study entry and discharge home
Time Frame: variable
|
variable
|
Length of hospitalization
Time Frame: variable
|
variable
|
Necrotizing enterocolitis
Time Frame: during the 14 day-study period and hospitalization
|
during the 14 day-study period and hospitalization
|
Electrolytes, bilirubin, serum urea nitrogen, creatinine and liver enzymes
Time Frame: 14 days
|
14 days
|
Infections
Time Frame: until discharge
|
until discharge
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gaelle Sadani, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre
- Principal Investigator: Louis Beaumier, MD, McGill University Health Centre/Research Institute of the McGill University Health Centre
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 09-225-PED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intestinal Disease
-
NorthSea Therapeutics B.V.RecruitingIntestinal Failure Associated Liver DiseaseUnited States
-
Pharmbio Korea Co., Ltd.CompletedColonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal DiseaseKorea, Republic of
-
Pharmbio Korea Co., Ltd.RecruitingColonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal DiseaseKorea, Republic of
-
Pharmbio Korea Co., Ltd.Not yet recruitingIntestinal Disease | Colonic Disease
-
Northwell HealthIpsenCompletedIntestinal Disease | Gastrointestinal Motility DisorderUnited States
-
University of California, IrvineMerck Sharp & Dohme LLCNot yet recruitingIntestinal DiseaseUnited States
-
Facet BiotechCompletedCrohn's Disease | Colitis | Digestive System Disease | Gastrointestinal Disease | Intestinal DiseaseUnited States, Canada
-
Protara TherapeuticsCompletedIntestinal Failure-associated Liver DiseaseUnited States, Denmark, United Kingdom, Italy
-
Shanghai Institute of Acupuncture, Moxibustion...Fudan University; Shanghai Jiao Tong University School of Medicine; Shanghai... and other collaboratorsRecruitingInflammatory Bowel Diseases | Crohn Disease | Intestinal DisorderChina
-
Tanta UniversityUnknownEsophageal Diseases | Pancreatic Diseases | Gastric Disease | Intestinal DiseaseEgypt
Clinical Trials on Lactated Ringer's Solution
-
Mahidol UniversityCompleted
-
Milton S. Hershey Medical CenterLehigh Valley Hospital; St. Luke's Hospital, Pennsylvania; The Reading Hospital...Completed
-
McGill University Health Centre/Research Institute...UnknownActual Impaired Fluid Volume
-
The First Affiliated Hospital with Nanjing Medical...RecruitingHepatic IschemiaChina
-
Dankook UniversityWonkwang University; University of UlsanCompletedPost-ERCP Acute PancreatitisKorea, Republic of
-
University of NottinghamUnknownPatients Undergoing Open Resection of Colorectal TumoursUnited Kingdom
-
Mahidol UniversityUnknownColonoscopy | Bowel Preparation
-
Yale UniversityRecruitingCoronary Artery Bypass Graft Surgery | Aortic Valve ReplacementUnited States
-
Zhongnan HospitalUnknownSeptic Shock | Intensive Care Unit | Fluid Resuscitation | Crystalloid SolutionChina
-
ZhiYong PengWu Jieping Medical FoundationUnknownSepsis | Septic Shock | Acute Kidney Injury | Sepsis, SevereChina